Journal article
Optimizing Chemotherapeutic Strategies for Peripheral T-Cell Lymphomas
Clinical lymphoma & myeloma, Vol.8, pp.S180-S186
12/2008
DOI: 10.3816/CLM.2008.s.014
PMID: 19073525
Abstract
Peripheral T-cell lymphomas are a heterogenous mix of histology, as well as clinical presentation, and outcome and remain a challenging group of diseases to treat. Because of difficulty and variability in diagnosis, improvements in diagnostic technology, and changing classification systems over time, the interpretation of studies is complicated. In addition, the response to current treatments and long-term outcome is generally poor. This review outlines these problems and discusses the current status of treatment strategies, including the disappointing results with standard anthracycline-based therapy as well as experience with modifications to CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone); increasing dose intensity; antimetabolites; and T-cell—targeted therapies. We conclude with a description of a new agent, pralatrexate, including the preclinical and early clinical experience as well as a description of a large phase II prospective trial. Because of the relative rarity of this group of diseases, large-scale prospective clinical trials are difficult to implement. New treatment strategies are needed if we hope to improve patient outcomes.
Details
- Title: Subtitle
- Optimizing Chemotherapeutic Strategies for Peripheral T-Cell Lymphomas
- Creators
- Lori J RosensteinBrian K Link
- Resource Type
- Journal article
- Publication Details
- Clinical lymphoma & myeloma, Vol.8, pp.S180-S186
- DOI
- 10.3816/CLM.2008.s.014
- PMID
- 19073525
- ISSN
- 1557-9190
- eISSN
- 1938-0712
- Language
- English
- Date published
- 12/2008
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094389402771
Metrics
13 Record Views